 |
|
|||||
|
NucSys
Consortium Training and Transfer of Knowledge (ToK) ESR Publications |
ESR1 (Tatjana Degenhardt)
Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) but
not PPARalpha serves as a plasma free fatty acid sensor in liver.
Sanderson LM, Degenhardt T, Koppen A, Kalkhoven E, Desvergne B,
Müller M, Kersten S. Mol Cell Biol. 2009 Dec;29(23):6257-67. Epub 2009 Oct
5. Population-level transcription cycles derive from stochastic timing of single-cell transcription. Degenhardt T, Rybakova KN, Tomaszewska A, Moné MJ, Westerhoff HV, Bruggeman FJ, Carlberg C. Cell. 2009 Aug 7;138(3):489-501.
Peroxisome proliferator-activated receptor alpha controls hepatic heme
biosynthesis through ALAS1.
Degenhardt T, Väisänen S, Rakhshandehroo M, Kersten S, Carlberg C.
J Mol Biol. 2009 May 1;388(2):225-38. Epub 2009 Mar 14.
Variations in the ghrelin receptor gene associate with obesity and glucose
metabolism in individuals with impaired glucose tolerance.
Mager U, Degenhardt T, Pulkkinen L, Kolehmainen M, Tolppanen AM,
Lindström J, Eriksson JG, Carlberg C, Tuomilehto J, Uusitupa M; Finnish
Diabetes Prevention Study Group. PLoS One. 2008 Aug 13;3(8):e2941.
Distinct HDACs regulate the transcriptional response of human
cyclin-dependent kinase inhibitor genes to Trichostatin A and
1alpha,25-dihydroxyvitamin D3.
Malinen M, Saramäki A, Ropponen A, Degenhardt T, Väisänen S,
Carlberg C. Nucleic Acids Res. 2008 Jan;36(1):121-32. Epub 2007 Nov 13.
Three members of the human pyruvate dehydrogenase kinase gene family are
direct targets of the peroxisome proliferator-activated receptor beta/delta.
Degenhardt T, Saramäki A, Malinen M, Rieck M, Väisänen S, Huotari
A, Herzig KH, Müller R, Carlberg C. J Mol Biol. 2007 Sep 14;372(2):341-55.
Epub 2007 Jul 19. Meta-analysis of primary target genes of peroxisome proliferator-activated receptors. Heinäniemi M, Uski JO, Degenhardt T, Carlberg C. Genome Biol. 2007;8(7):R147.
The insulin-like growth factor-binding protein 1 gene is a primary target of peroxisome proliferator-activated receptors. Degenhardt T, Matilainen M, Herzig KH, Dunlop TW, Carlberg C. J Biol Chem. 2006 Dec 22;281(51):39607-19. Epub 2006 Oct 24.
ESR2 (Aleksandra Tomaszewska)
Population-level transcription cycles derive from stochastic timing of single-cell transcription. Degenhardt T, Rybakova KN, Tomaszewska A, Moné MJ, Westerhoff HV, Bruggeman FJ, Carlberg C. Cell. 2009 Aug 7;138(3):489-501.
ESR3 (Sebastiano Battaglia)
Elevated NCOR1 disrupts a network of dietary-sensing nuclear receptors in bladder cancer cells. Abedin SA, Thorne JL, Battaglia S, Maguire O, Hornung LB, Doherty AP, Mills IG, Campbell MJ. Carcinogenesis. 2009 Mar;30(3):449-56. Epub 2009 Jan 6
ESR4 (Pedro Velica)
Lack of functional and expression homology between human and mouse aldo-keto reductase 1C enzymes: implications for modelling human cancers. Velica P, Davies NJ, Rocha PP, Schrewe H, Ride JP, Bunce CM. Mol Cancer. ;8(1):121. [Epub ahead of print]
Prostaglandins in muscle regeneration. Veliça P, Bunce CM. J Muscle Res Cell Motil. 2008;29(6-8):163-7. Epub 2008 Dec 4. Review.
ESR5 (Claudia Bruedigam)
Evidence for multiple peroxisome proliferator-activated receptor gamma transcripts in bone: fine-tuning by hormonal regulation and mRNA stability. Bruedigam C, Koedam M, Chiba H, Eijken M, van Leeuwen JP. FEBS Lett. 2008 May 14;582(11):1618-24. Epub 2008 Apr 22.
ESR6 (Vioala Wöckel)
None
ESR7 (Ellen Wiedemann)
None
ESR8 (Ekaterina (“Katja”) Rybakova)
Population-level transcription cycles derive from stochastic timing of single-cell transcription. Degenhardt T, Rybakova KN, Tomaszewska A, Moné MJ, Westerhoff HV, Bruggeman FJ, Carlberg C. Cell. 2009 Aug 7;138(3):489-501.
Systems biology towards life in silico: mathematics of the control of living cells. Westerhoff HV, Kolodkin A, Conradie R, Wilkinson SJ, Bruggeman FJ, Krab K, van Schuppen JH, Hardin H, Bakker BM, Moné MJ, Rybakova KN, Eijken M, van Leeuwen HJ, Snoep JL. J Math Biol. 2009 Jan;58(1-2):7-34. Epub 2008 Feb 16.
ESR9 (Alexey Kolodkin)
Systems biology towards life in silico: mathematics of the control of living cells. Westerhoff HV, Kolodkin A, Conradie R, Wilkinson SJ, Bruggeman FJ, Krab K, van Schuppen JH, Hardin H, Bakker BM, Moné MJ, Rybakova KN, Eijken M, van Leeuwen HJ, Snoep JL. J Math Biol. 2009 Jan;58(1-2):7-34. Epub 2008 Feb 16.
ESR10 (Anastasia Georgiadi)
None
ESR11 (Marcin Buler)
None
ESR12 (Carsten Kriebitsch)
None
ESR13 (Radu Oita)
Visfatin induces oxidative stress in differentiated C2C12 myotubes in an Akt- and MAPK-independent, NFkB-dependent manner. Oita RC, Ferdinando D, Wilson S, Bunce C, Mazzatti DJ. Pflugers Arch. 2009 Nov 8. [Epub ahead of print].
Whole-genome microarray analysis identifies up-regulation of Nr4a nuclear receptors in muscle and liver from diet-restricted rats. Oita RC, Mazzatti DJ, Lim FL, Powell JR, Merry BJ. Mech Ageing Dev. 2009 Apr;130(4):240-7. Epub 2008 Dec 27.
Muscle unloading-induced metabolic remodeling is associated with acute alterations in PPARdelta and UCP-3 expression. Mazzatti DJ, Smith MA, Oita RC, Lim FL, White AJ, Reid MB. Physiol Genomics. 2008 Jul 15;34(2):149-61. Epub 2008 Apr 29.
ESR14 (Fabio Pereira)
Snail2 cooperates with Snail1 in the repression of vitamin D receptor in colon cancer. Larriba MJ, Martín-Villar E, García JM, Pereira F, Peńa C, de Herreros AG, Bonilla F, Muńoz A. Carcinogenesis. 2009 Aug;30(8):1459-68. Epub 2009 Jun 5.
Vitamin D and Wnt/beta-catenin pathway in colon cancer: role and regulation of DICKKOPF genes. Pendás-Franco N, Aguilera O, Pereira F, González-Sancho JM, Muńoz A. Anticancer Res. 2008 Sep-Oct;28(5A):2613-23. Review
ESR15 (Pedro Rocha)
Lack of functional and expression homology between human and mouse aldo-keto reductase 1C enzymes: implications for modelling human cancers. Velica P, Davies NJ, Rocha PP, Schrewe H, Ride JP, Bunce CM. Mol Cancer. ;8(1):121. [Epub ahead of print].
ESR16 (Carole Brosseau)
None
ESR17 (Thomas Nittke)
The Candidate Oncogene CYP24A1: A Potential Biomarker for Colorectal Tumorigenesis. Horváth HC, Lakatos P, Kósa JP, Bácsi K, Borka K, Bises G, Nittke T, Hershberger PA, Speer G, Kállay E. J Histochem Cytochem. 2009 Nov 9.
Parallel elevation of colonic 1,25-dihydroxyvitamin D3 levels and apoptosis in female mice on a calcium-deficient diet. Nittke T, Kallay E, Manhardt T, Cross HS. Anticancer Res. 2009 Sep;29(9):3727-32.
Modulation of vitamin D synthesis and catabolism in colorectal mucosa: a new target for cancer prevention. Cross HS, Nittke T, Peterlik M. Anticancer Res. 2009 Sep;29(9):3705-12. Review.
Nutritional calcium modulates colonic expression of vitamin D receptor and pregnane X receptor target genes. Nittke T, Selig S, Kallay E, Cross HS. Mol Nutr Food Res. 2008 Jun;52 Suppl 1:S45-51.
ESR18 (Gilles Laverny)
Synthesis and anti-inflammatory properties of 1alpha,25-dihydroxy-16-ene-20-cyclopropyl-24-oxo-vitamin D3, a hypocalcemic, stable metabolite of 1alpha,25-dihydroxy-16-ene-20-cyclopropyl-vitamin D3. Laverny G, Penna G, Uskokovic M, Marczak S, Maehr H, Jankowski P, Ceailles C, Vouros P, Smith B, Robinson M, Reddy GS, Adorini L. J Med Chem. 2009 Apr 23;52(8):2204-13.
Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. Penna G, Fibbi B, Amuchastegui S, Cossetti C, Aquilano F, Laverny G, Gacci M, Crescioli C, Maggi M, Adorini L. J Immunol. 2009 Apr 1;182(7):4056-64.
The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Penna G, Fibbi B, Amuchastegui S, Corsiero E, Laverny G, Silvestrini E, Chavalmane A, Morelli A, Sarchielli E, Vannelli GB, Gacci M, Colli E, Maggi M, Adorini L. Prostate. 2009 Apr 1;69(5):480-93.
Vitamin D receptor agonists in the treatment of autoimmune diseases: selective targeting of myeloid but not plasmacytoid dendritic cells. Penna G, Amuchastegui S, Laverny G, Adorini L. J Bone Miner Res. 2007 Dec;22 Suppl 2:V69-73. Review.
|
|||||
NucSys: Systems biology of nuclear receptors: A nutrigenomic approach to aging-related diseases |
